Skip to main content
SpringerLink
Log in

Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy

  • B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Armitage, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Mantle cell lymphoma (MCL) is a heterogeneous disease, and it has been well-established over the last decade that a subset of patients can have indolent presentation. It is therefore important to adopt a risk-stratified approach in order to minimize unnecessary toxicities while maximizing survival and quality of life in selected MCL patients. This review provides an up-to-date assessment of clinical and pathologic entities associated with indolent disease course and delineates available biomarkers with predictive significance. Initial treatment decisions should be guided by risk assessment to discern patients who might do well with deferred therapy, from those who would require treatment with non-aggressive first-line regimens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Campo E, Rule S. Mantle cell lymphoma: evolving management strategies. Blood. 2015;125:48–55.

    Article  CAS  PubMed  Google Scholar 

  2. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27:511–8.

    Article  PubMed  Google Scholar 

  3. Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol. 2002;20:1288–94.

    Article  CAS  PubMed  Google Scholar 

  4. Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372:944–53.

    Article  CAS  PubMed  Google Scholar 

  5. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203–10.

    Article  CAS  PubMed  Google Scholar 

  6. Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367:520–31.

    Article  CAS  PubMed  Google Scholar 

  7. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005;23:7013–23.

    Article  CAS  PubMed  Google Scholar 

  8. Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112:2687–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Delarue R, Haioun C, Ribrag V, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d’Etude des Lymphomes de l’Adulte. Blood. 2013;121:48–53.

    Article  CAS  PubMed  Google Scholar 

  10. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27:1209–13.

    Article  PubMed  Google Scholar 

  11. Nygren L, Baumgartner Wennerholm S, Klimkowska M, et al. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood. 2012;119:4215–23.

    Article  CAS  PubMed  Google Scholar 

  12. Abrahamsson A, Albertsson-Lindblad A, Brown PN, et al. Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. Blood. 2014;124:1288–95. A comprehensive population-based analysis of initial treatment and outcome of MCL patients.

    Article  CAS  PubMed  Google Scholar 

  13. Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol. 2005;131:29–38.

    Article  PubMed  Google Scholar 

  14. Hoster E, Rosenwald A, Berger F et al. Prognostic value of ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network. Journal of Clinical Oncology 2016. Up-to-date assessment of predictive value of MIPI and Ki-67 individually and in combination.

  15. Carvajal-Cuenca A, Sua LF, Silva NM, et al. In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica. 2012;97:270–8.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Orchard J, Garand R, Davis Z, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood. 2003;101:4975–81.

    Article  CAS  PubMed  Google Scholar 

  17. Ondrejka SL, Lai R, Smith SD, Hsi ED. Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica. 2011;96:1121–7.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Royo C, Navarro A, Clot G, et al. Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia. 2012;26:1895–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Camacho FI, Algara P, Rodriguez A, et al. Molecular heterogeneity in MCL defined by the use of specificV H genes and the frequency of somatic mutations. Blood. 2003;101:4042–6.

    Article  CAS  PubMed  Google Scholar 

  20. Hsi ED, Martin P. Indolent mantle cell lymphoma. Leuk Lymphoma. 2014;55:761–7. An excellent review of indolent MCL.

    Article  PubMed  Google Scholar 

  21. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558–65.

    Article  CAS  PubMed  Google Scholar 

  22. Hoster E, Klapper W, Hermine O, et al. Confirmation of the mantle-cell lymphoma international prognostic index in randomized trials of the european mantle-cell lymphoma network. J Clin Oncol. 2014;32:1338–46.

    Article  PubMed  Google Scholar 

  23. Geisler CH, Kolstad A, Laurell A, et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood. 2010;115:1530–3.

    Article  CAS  PubMed  Google Scholar 

  24. Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood. 2008;111:2385–7.

    Article  CAS  PubMed  Google Scholar 

  25. Dreyling M, Ferrero S, Vogt N, Klapper W. New paradigms in mantle cell lymphoma: is it time to risk-stratify treatment based on the proliferative signature? Clin Cancer Res. 2014;20:5194–206.

    Article  CAS  PubMed  Google Scholar 

  26. Vegliante MC, Palomero J, Pérez-Galán P, et al. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood. 2013;121:2175–85.

    Article  CAS  PubMed  Google Scholar 

  27. Palomero J, Vegliante MC, Rodríguez ML, et al. SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma. Blood. 2014;124:2235–47.

    Article  CAS  PubMed  Google Scholar 

  28. Fernàndez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010;70:1408–18.

    Article  PubMed  Google Scholar 

  29. Hadzidimitriou A, Agathangelidis A, Darzentas N, et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood. 2011;118:3088–95.

    Article  CAS  PubMed  Google Scholar 

  30. Kienle D, Kröber A, Katzenberger T, et al. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood. 2003;102:3003–9.

    Article  CAS  PubMed  Google Scholar 

  31. Walsh SH, Thorsélius M, Johnson A, et al. Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. Blood. 2003;101:4047–54.

    Article  CAS  PubMed  Google Scholar 

  32. Navarro A, Clot G, Royo C, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012;72:5307–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Slotta-Huspenina J, Koch I, de Leval L, et al. The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index. Haematologica. 2012;97:1422–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Greiner T, Moynihan M, Chan W, et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood. 1996;87:4302–10.

    CAS  PubMed  Google Scholar 

  35. Hernandez L, Fest T, Cazorla M, et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood. 1996;87:3351–9.

    CAS  PubMed  Google Scholar 

  36. Nordström L, Sernbo S, Eden P, et al. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma—a Nordic Lymphoma Group study. Br J Haematol. 2014;166:98–108.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867–74.

    Article  PubMed  Google Scholar 

  38. Goy A, Bernstein SH, McDonald A, et al. Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial. Leuk Lymphoma. 2010;51:1269–77.

    Article  CAS  PubMed  Google Scholar 

  39. Gribben JG, Fowler N, Morschhauser F. Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol. 2015;33:2803–11.

    Article  CAS  PubMed  Google Scholar 

  40. Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31:3688–95.

    Article  CAS  PubMed  Google Scholar 

  41. Trneny M, Lamy T, Walewski J, et al. Phase II randomized, multicenter study of lenalidomide vs best investigator’s choice in relapsed/refractory mantle cell lymphoma: results of the MCL-002 (SPRINT) study. Blood. 2014;124:626.

    Google Scholar 

  42. Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012;13:716–23.

    Article  PubMed  Google Scholar 

  43. Ruan J, Martin P, Shah B, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med. 2015;373:1835–44. A first proof-of-principal study demonstrating that non-chemotherapy biologic combination can be highly effective as initial therapy in MCL.

    Article  PubMed  Google Scholar 

  44. Goy A, Kalayoglu Besisik S, Drach J, et al. Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial. Br J Haematol. 2015;170:496–503.

    Article  CAS  PubMed  Google Scholar 

  45. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126:739–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Wang ML, Lee H, Chuang H et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol 17: 48–56.

  48. Gressin R, Callanan M, Daguindau N et al. Frontline therapy with the Ribvd Regimen elicits high clinical and molecular response rates and long PFS in elderly patients mantle cell lymphoma (MCL); Final Results of a Prospective Phase II Trial By the Lysa Group. 2014

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Medical Oncology, Meyer Cancer Center, Weill Cornell Medical College, 1305 York Avenue, New York, NY, 10065, USA

    Jia Ruan & Peter Martin

Authors
  1. Jia Ruan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jia Ruan.

Ethics declarations

Conflict of Interest

Jia Ruan reports research funding from Celgene, Janssen, Pharmacyclics, and Seattle Genetics. Dr. Ruan reports consulting, speaker’s bureau, or advisory board meeting for Celgene, Janssen, Pharmacyclics, and Seattle Genetics.

Peter Martin reports research funding from Millennium, Gilead, Celgene, and Phamacyclics. Dr. Martin reports consulting, speaker’s bureau, or advisory board meeting for Acerta, Celgene, Gilead, Janssen, and Novartis.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on B-cell NHL, T-cell NHL, and Hodgkin Lymphoma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ruan, J., Martin, P. Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy. Curr Hematol Malig Rep 11, 234–240 (2016). https://doi.org/10.1007/s11899-016-0324-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-016-0324-3

Keywords

Search

Navigation